

- c. HARRIS, J. D. AND OLINER, L. Simultaneous Resin Uptake Studies of Labeled T-4 and T-3 in Thyroid Disease. *Journal of Nuclear Medicine* 7:259, 1966.
2. a. RABINOWITZ, J. AND SHAPIRO, B. Observations on Uptake of T-3 by Erythrocytes. *Journal of Nuclear Medicine* 3:709, 1962.
b. STERLING, K. AND TABACHNIK. Resin Uptake of T-3 as a Test of Thyroid Function. *Journal of Clinical Endocrin.* 21:456, 1961.
c. LEE, N. ETAL. A Study of Variables Affecting the Ion Exchange Resin Uptake of T-3 from Sera. *Clinical Chem.* 10:136, 1964.
3. TANFORD, C. *Physical Chemistry of Macromolecules*. John Wiley and Sons, 1961, page 547, 307, 357, 358, etc.
4. QUARF, M., MASON, S. T-3 Sponge Resin Uptake Values in Man and Sheep. *Journal of Nuclear Medicine* 6:192, 1965.
5. a. MANFREDI, O. ETAL. I-131, T-3 Resin Sponge Uptake using Ice-water Bath Incubation. *J. Nuc. Med.* 7:72, 1966.
b. GOOLDEN, A. ETAL. An Evaluation of the T-3 Resin Sponge Test. *Jour. Clin. End.* 25:125, 1965.
c. MANUYAMA, I. AND CHAMBERS, J. B. Binding of T4 by Intact Erythrocytes, etc. *Fed. Proc.* 25:686, 1966.
6. a. WILLIAMS, ETAL. Thyroid Function and Enovid. *Obs. Gyn.* 27:232, 1966.
b. POTSAID, M. AND KOLODNY. In Vitro Uptake of Tagged T-3. *Am. J. Roent.* 96:725, 1966.
7. a. GOTTLIEB, C. AND HERBERT, V. Desorption from Coated Charcoal—An Alternative to the Coated Charcoal Test. *J. Lab. and Clin. Med.* 68:113, July, 1966.
b. HERBERT, V. AND GOTTLIEB, C. A Modified Charcoal T-3 Test. *Clin. Res.* 13:532, 1965.
8. SCHOLLER, J. F. A Simple Measure of Thyrobinding by Plasma. A Test of Thyroid Function. *Jour. Nuc. Med.* 3:41, 1962.
9. CAVALLIERI, R. AND SEARLE, G. Dialysis of I-131 T-3 from Plasma—*J. Lab. Clin. Med.* 65:171, 1965.

Society of Nuclear Medicine
Call for Abstracts-Scientific Program
15th Annual Meeting St. Louis, Missouri
Chase-Park Plaza Hotel June 27-30, 1968

The Scientific Program Committee welcomes the submission of abstracts of original contributions for both members and non-members on the following basic scientific aspects of Nuclear Medicine: Investigative Nuclear Medicine, New Clinical Applications or Original Observations; Nuclear Medicine—Its Role in Medical Practice; New Pharmaceutical Agent Development and Evolution; Advances in Nuclear Medicine Technology and Instrumentation Development; Short Communications (five minute presentations).

Include in your abstract: Title of Paper and Name(s) of author(s) and institution(s) (underline name of presentation author); purpose, methods, results and/or conclusions. Limit paper to a maximum of 300 words suitable for final program publication and the Journal. Give accurate mailing address.

Send abstracts on, or before February 1, 1968 to:

George V. Taplin, M.D.
Chairman, Program Committee, Society of Nuclear Medicine
UCLA Laboratory of Nuclear Medicine & Radiation Biology
900 Veteran Avenue, Los Angeles, California 90024